Biotech Archives - Spark Newswire

1 minute read

Nanobiotix Announces Presentation Of The Final Efficacy Analysis From Phase 1 Cohort Expansion Evaluating NBTXR3 In Locally Advanced Head And Neck Cancer Showing Median Progression-Free Survival Of 16.9 Months And Median Overall Survival Of 23.1 Months

Today, 4:34 PM

Final data from Study 102 Dose Expansion show that radiotherapy-activated NBTXR3 was feasible and well tolerated in elderly patients with a high burden of comorbidity (n=56)Consistently high injected-lesion overall

NBTX

3 minute read

New Data From Phase 3 Trial Further Validate Prognostic Value Of Veracyte’s Decipher Prostate Genomic Classifier

By Benzinga Newsdesk

Today, 4:12 PM

Findings presented at the 2023 ASTRO Annual Meeting expand substantial body of evidence demonstrating Decipher Prostate test's ability to help inform prostate cancer treatment decisions.Additional study suggests level of

VCYT

1 minute read

Revolution Medicines To Present New Clinical Data At Major Oncology Conferences And Host Investor Webcast

By Benzinga Newsdesk

Today, 4:11 PM

Interim Data to be Presented for RMC-6236 (RASMULTI(ON) Inhibitor) and RMC-6291 (RASG12C(ON) Inhibitor) Company to Host Investor Webcast Following ESMO Data Presentation on October 22 at 12:30 p.m.

RVMD

1 minute read

Novavax’s COVID-19 Shot Just In Time, Optimism Surrounds As Demand Picks Up Momentum

By Vandana Singh

Today, 3:19 PM

Tuesday, the FDA granted an emergency use nod to Novavax Inc's (NASDAQ: NVAX) COVID-19 Vaccine, Adjuvanted (2023-2024 Formula) (NVX-CoV2601) for active immunization to prevent COVID-19 in

NVAX

1 minute read

Loxo@Lilly Unveils Three New Oncology Programs At 2023 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics

By Benzinga Newsdesk

Today, 12:07 PM

The poster presentations will include preclinical characterization data for a highly potent inhibitor of KRAS G12D that is selective against wild-type KRAS, a highly potent and isoform-selective pan-KRAS inhibitor with

LLY

3 minute read

Nature Publishes Discovery And Preclinical Results For ABBV-CLS-484, A Potential First-In-Class PTPN2/N1 Inhibitor In Cancer Immunotherapy

By Benzinga Newsdesk

Today, 11:09 AM

AbbVie (NYSE:ABBV), the Broad Institute of MIT and Harvard, and Calico Life Sciences today announced the publication in Nature of the discovery and preclinical data that demonstrate investigational ABBV-CLS-484 is a

ABBV

1 minute read

Why Is Gene Therapy Player Freeline Therapeutics Stock Trading Higher Today?

By Vandana Singh

Today, 10:23 AM

Freeline Therapeutics Holdings plc (NASDAQ: FRLN) reported initial data from the ongoing Phase 1/2 GALILEO-1 trial of FLT201, its adeno-associated virus (AAV) gene therapy candidate,

FRLN

3 minute read

Peer-Reviewed Independent Study Published In Microbiology Spectrum Finds Cue Health’s Molecular COVID-19 Test Is As Accurate As A Lab-Based PCR Test

By Benzinga Newsdesk

Today, 9:21 AM

In largest-of-its-kind clinical study on asymptomatic people, Cue demonstrated 99.4% accuracy compared to lab-based PCRCue Health (NASDAQ:HLTH), a healthcare technology company, announced today the peer-reviewed

HLTH

3 minute read

New MRD Publication In Unresectable Stage I-III Lung Cancer Demonstrates Signatera’s Ability To Risk Stratify And Detect Progression Early

By Benzinga Newsdesk

Today, 9:06 AM

Test performance showed 82% pre-treatment detection, with 100% longitudinal sensitivity and 100% longitudinal specificity to disease progressionNatera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA testing, today

NTRA